Table 1.
Patients’ characteristics.
| Characteristics | Number (%) |
|---|---|
| Age (median, range) | 62 (37–86) |
| ECOG PS (median, range) | 0 (0–2) |
| De novo disease | 14 (34.1) |
| ER status | |
| Positive | 34 (82.9) |
| Negative | 7 (17.1) |
| PgR status | |
| Positive | 28 (68.3) |
| Negative | 13 (31.7) |
| Triple negative | 6 (14.6) |
| HER2 status | |
| Positive | 3 (7.3) |
| Negative | 38 (92.7) |
| Neo/adjuvant CT (*) | 20 (74.1) |
| Adjuvant ET (*) | 22 (81.5) |
| Number of previous CT lines for advanced disease | |
| 1 | 10 (24.4) |
| 2 | 20 (48.8) |
| 3 | 5 (12.2) |
| ≥4 | 6 (14.6) |
| Median, range | 2 (1–6) |
| Number of previous ET lines for advanced disease | |
| 1 | 6 (14.6) |
| 2 | 15 (36.6) |
| ≥3 | 11 (26.8) |
| Median, range | 2 (0–4) |
| Number of organs involved | |
| 1 | 3 (7.3) |
| 2 | 14 (34.1) |
| ≥3 | 24 (58.5) |
| Median, range | 3 (1–6) |
| Most common metastatic sites | |
| Bone | 31 (75.6) |
| Liver | 29 (70.7) |
| Soft tissue | 27 (65.8) |
| Lung | 17 (41.5) |
| Pleura | 7 (17.1) |
| CNS | 5 (12.2) |
| Peritoneum | 4 (9.7) |
(*) Numbers and percentages refer to 27 patients since 14 patients were metastatic at presentation. CNS, central nervous system; CT, chemotherapy; ECOG PS, Eastern Cooperative Oncology Group performance status; ER, estrogen receptor; PgR, progesterone receptor; ET, endocrine therapy; HER2, Human Epidermal Growth Factor Receptor 2.